

Claudio Maria Mastroianni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3011138/publications.pdf>

Version: 2024-02-01

343
papers

8,605
citations

57631

44
h-index

85405

71
g-index

351
all docs

351
docs citations

351
times ranked

13520
citing authors

#	ARTICLE	IF	CITATIONS
1	Central obesity, smoking habit, and hypertension are associated with lower antibody titres in response to COVID-19 mRNA vaccine. <i>Diabetes/Metabolism Research and Reviews</i> , 2022, 38, e3465.	1.7	203
2	Personalized profiles of antioxidant signaling pathway in patients with tuberculosis. <i>Journal of Microbiology, Immunology and Infection</i> , 2022, 55, 405-412.	1.5	3
3	SARS-CoV-2 vaccination with BNT162B2 in renal transplant patients: Risk factors for impaired response and immunological implications. <i>Clinical Transplantation</i> , 2022, 36, e14495.	0.8	40
4	Early IgG / IgA response in hospitalized COVID-19 patients is associated with a less severe disease. <i>Diagnostic Microbiology and Infectious Disease</i> , 2022, 102, 115586.	0.8	3
5	Covid-19 sequelae in working age patients: A systematic review. <i>Journal of Medical Virology</i> , 2022, 94, 858-868.	2.5	26
6	PaO ₂ /FiO ₂ ratio forecasts COVID-19 patients' outcome regardless of age: a cross-sectional, monocentric study. <i>Internal and Emergency Medicine</i> , 2022, 17, 665-673.	1.0	11
7	Comparison of Thrombotic Events and Mortality in Patients with Community-Acquired Pneumonia and COVID-19: A Multicenter Observational Study. <i>Thrombosis and Haemostasis</i> , 2022, 122, 257-266.	1.8	18
8	Infectious risk in multiple sclerosis patients treated with disease-modifying therapies: A three-year observational cohort study. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2022, 8, 205521732110657.	0.5	4
9	The Interplay between Host Defense, Infection, and Clinical Status in Septic Patients: A Narrative Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 803.	1.8	8
10	Diagnostic Value of JC Polyomavirus Viruria, Viremia, Serostatus and microRNA Expression in Multiple Sclerosis Patients Undergoing Immunosuppressive Treatment. <i>Journal of Clinical Medicine</i> , 2022, 11, 347.	1.0	4
11	Epidemiology of SARS-CoV-2 Infection in Italy Using Real-World Data: Methodology and Cohort Description of the Second Phase of Web-Based EPICoVID19 Study. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 1274.	1.2	4
12	Distribution of Interferon Lambda 4 Single Nucleotide Polymorphism rs11322783 Genotypes in Patients with COVID-19. <i>Microorganisms</i> , 2022, 10, 363.	1.6	4
13	HPV Vaccination after Primary Treatment of HPV-Related Disease across Different Organ Sites: A Multidisciplinary Comprehensive Review and Meta-Analysis. <i>Vaccines</i> , 2022, 10, 239.	2.1	24
14	High Activity of N-Acetylcysteine in Combination with Beta-Lactams against Carbapenem-Resistant <i>Klebsiella pneumoniae</i> and <i>Acinetobacter baumannii</i> . <i>Antibiotics</i> , 2022, 11, 225.	1.5	8
15	Analysis of serum microRNAs and rs2910164 GC single-nucleotide polymorphism of miRNA-146a in COVID-19 patients. <i>Journal of Immunoassay and Immunochemistry</i> , 2022, 43, 347-364.	0.5	7
16	Long-Term Subjective and Objective Assessment of Smell and Taste in COVID-19. <i>Cells</i> , 2022, 11, 788.	1.8	10
17	Role of Tocilizumab in Down Regulating sCD163 Plasmatic Levels in a Cohort of COVID-19 Patients. <i>Frontiers in Immunology</i> , 2022, 13, 871592.	2.2	3
18	Phylogeography and genomic epidemiology of SARS-CoV-2 in Italy and Europe with newly characterized Italian genomes between February-June 2020. <i>Scientific Reports</i> , 2022, 12, 5736.	1.6	6

#	ARTICLE	IF	CITATIONS
19	Switching to a Bictegravir Single Tablet Regimen in Elderly People Living with HIV-1: Data Analysis from the BICTEL Cohort. <i>Diagnostics</i> , 2022, 12, 76.	1.3	9
20	Anti-IFN- γ neutralizing antibodies from COVID-19 patients correlate with downregulation of IFN response and laboratory biomarkers of disease severity. <i>European Journal of Immunology</i> , 2022, 52, 1120-1128.	1.6	29
21	Convalescent plasma for haematological patients with SARS-CoV-2 pneumonia and severe depletion of B-cell lymphocytes following anti-CD20 therapy: a single-centre experience and review of the literature.. <i>New Microbiologica</i> , 2022, 45, 62-72.	0.1	3
22	Prognostic Value of 12-Leads Electrocardiogram at Emergency Department in Hospitalized Patients with Coronavirus Disease-19. <i>Journal of Clinical Medicine</i> , 2022, 11, 2537.	1.0	4
23	Epidemiology, aetiology and treatment of skin and soft tissue infections: final report of a prospective multicentre national registry. <i>Journal of Chemotherapy</i> , 2022, 34, 524-533.	0.7	3
24	Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine in adult patients with systemic sclerosis. <i>Clinical Rheumatology</i> , 2022, 41, 2755-2763.	1.0	6
25	Clinical Characteristics and Outcome of Hospitalized COVID-19 Patients Treated with Standard Dose of Dexamethasone or High Dose of Methylprednisolone. <i>Biomedicines</i> , 2022, 10, 1548.	1.4	2
26	COVID-19 Severity and Androgen Receptor Polymorphism. <i>Biology</i> , 2022, 11, 974.	1.3	1
27	Post-Traumatic Stress Disorder Trajectories the Year after COVID-19 Hospitalization. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 8452.	1.2	10
28	qSOFA as a new community-acquired pneumonia severity score in the emergency setting. <i>Emergency Medicine Journal</i> , 2021, 38, 906-912.	0.4	3
29	Is Albumin Predictor of Mortality in COVID-19?. <i>Antioxidants and Redox Signaling</i> , 2021, 35, 139-142.	2.5	136
30	Targeting the NO-GMP-PDE5 pathway in COVID-19 infection. The DEDALO project. <i>Andrology</i> , 2021, 9, 33-38.	1.9	47
31	Major reduction of NKT cells in patients with severe COVID-19 pneumonia. <i>Clinical Immunology</i> , 2021, 222, 108630.	1.4	39
32	Ozone as adjuvant support in the treatment of COVID-19: A preliminary report of probiozovid trial. <i>Journal of Medical Virology</i> , 2021, 93, 2210-2220.	2.5	22
33	Testosterone target therapy: focus on immune response, controversies and clinical implications in patients with COVID-19 infection. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2021, 12, 204201882110101.	1.4	24
34	Targeting Microbiome: An Alternative Strategy for Fighting SARS-CoV-2 Infection. <i>Chemotherapy</i> , 2021, 66, 24-32.	0.8	22
35	Beyond Bone: Infectious Diseases and Immunity in Parathyroid Disorders. <i>Advances in Experimental Medicine and Biology</i> , 2021, , 17-32.	0.8	3
36	Molecular Identification of New Cases of Human Dirofilariasis (<i>Dirofilaria repens</i>) in Italy. <i>Pathogens</i> , 2021, 10, 251.	1.2	14

#	ARTICLE	IF	CITATIONS
37	Procalcitonin in daily clinical practice: an evergreen tool also during a pandemic. <i>Internal and Emergency Medicine</i> , 2021, 16, 541-543.	1.0	7
38	Increased sCD163 and sCD14 Plasmatic Levels and Depletion of Peripheral Blood Pro-Inflammatory Monocytes, Myeloid and Plasmacytoid Dendritic Cells in Patients With Severe COVID-19 Pneumonia. <i>Frontiers in Immunology</i> , 2021, 12, 627548.	2.2	149
39	Modeling the Contribution of Male Testosterone Levels to the Duration of Positive COVID Testing among Hospitalized Male COVID-19 Patients. <i>Diagnostics</i> , 2021, 11, 581.	1.3	9
40	Post-traumatic Stress Disorder Among COVID-19 Survivors at 3-Month Follow-up After Hospital Discharge. <i>Journal of General Internal Medicine</i> , 2021, 36, 1702-1707.	1.3	98
41	Does Lung Ultrasound Have a Role in the Clinical Management of Pregnant Women with SARS COV2 Infection?. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 2762.	1.2	8
42	Effect of N-Acetylcysteine Administration on 30-Day Mortality in Critically Ill Patients with Septic Shock Caused by Carbapenem-Resistant <i>Klebsiella pneumoniae</i> and <i>Acinetobacter baumannii</i> : A Retrospective Case-Control Study. <i>Antibiotics</i> , 2021, 10, 271.	1.5	13
43	Therapeutic strategies for severe COVID-19: a position paper from the Italian Society of Infectious and Tropical Diseases (SIMIT). <i>Clinical Microbiology and Infection</i> , 2021, 27, 389-395.	2.8	37
44	Differential induction of type I and III interferon genes in the upper respiratory tract of patients with coronavirus disease 2019 (COVID-19). <i>Virus Research</i> , 2021, 295, 198283.	1.1	26
45	Alteration of type I interferon response is associated with subclinical atherosclerosis in virologically suppressed HIV-1 infected male patients. <i>Journal of Medical Virology</i> , 2021, 93, 4930-4938.	2.5	5
46	Low-Grade Endotoxemia and Thrombosis in COVID-19. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00348.	1.3	32
47	Early antibiotic treatment in emergency department: the critical balance. <i>Internal and Emergency Medicine</i> , 2021, 16, 1743-1745.	1.0	0
48	Tocilizumab effects in COVID-19 pneumonia: role of CT texture analysis in quantitative assessment of response to therapy. <i>Radiologia Medica</i> , 2021, 126, 1170-1180.	4.7	22
49	Efficacy and durability of two vs three drug integrase inhibitor based regimens in virologically suppressed HIV-1 infected patients: Data from real life ODOACRE cohort. <i>HIV Medicine</i> , 2021, 22, 843-853.	1.0	18
50	Persistent Systemic Microbial Translocation and Intestinal Damage During Coronavirus Disease-19. <i>Frontiers in Immunology</i> , 2021, 12, 708149.	2.2	35
51	Arterial and venous thrombosis in coronavirus 2019 disease (Covid-19): relationship with mortality. <i>Internal and Emergency Medicine</i> , 2021, 16, 1231-1237.	1.0	20
52	Antiretroviral Therapy Dampens Mucosal CD4+ T Lamina Propria Lymphocytes Immune Activation in Long-Term Treated People Living with HIV-1. <i>Microorganisms</i> , 2021, 9, 1624.	1.6	1
53	Clinical Characteristics and Outcome of Patients with Suspected COVID-19 in Emergency Department (RESILIENCY Study II). <i>Diagnostics</i> , 2021, 11, 1368.	1.3	3
54	Oxygen Sparing Effect of Bacteriotherapy in COVID-19. <i>Nutrients</i> , 2021, 13, 2898.	1.7	9

#	ARTICLE	IF	CITATIONS
55	Prevalence and clinical significance of relative bradycardia at hospital admission in patients with coronavirus disease 2019 (COVID-19). <i>Clinical Microbiology and Infection</i> , 2021, 27, 1185-1187.	2.8	13
56	Efficacy of Remdesivir-Containing Therapy in Hospitalized COVID-19 Patients: A Prospective Clinical Experience. <i>Journal of Clinical Medicine</i> , 2021, 10, 3784.	1.0	12
57	Cardiac involvement in consecutive unselected hospitalized COVID-19 population: In-hospital evaluation and one-year follow-up. <i>International Journal of Cardiology</i> , 2021, 339, 235-242.	0.8	28
58	Role of Serum E-Selectin as a Biomarker of Infection Severity in Coronavirus Disease 2019. <i>Journal of Clinical Medicine</i> , 2021, 10, 4018.	1.0	11
59	The Synergistic Effect of Time of Exposure, Distance and No Use of Personal Protective Equipment in the Determination of SARS-CoV-2 Infection: Results of a Contact Tracing Follow-Up Study in Healthcare Workers. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 9456.	1.2	3
60	An observed association between conjunctivitis and severity of COVID-19. <i>Journal of Infection</i> , 2021, 83, 381-412.	1.7	8
61	Depressive Symptoms among Individuals Hospitalized with COVID-19: Three-Month Follow-Up. <i>Brain Sciences</i> , 2021, 11, 1175.	1.1	9
62	Real-life use of tocilizumab with or without corticosteroid in hospitalized patients with moderate-to-severe COVID-19 pneumonia: A retrospective cohort study. <i>PLoS ONE</i> , 2021, 16, e0257376.	1.1	6
63	Early IgG / IgA response in hospitalized COVID-19 patients is associated with a less severe disease.. <i>Diagnostic Microbiology and Infectious Disease</i> , 2021, 105, 115539.	0.8	0
64	CURB-65 plus hypoalbuminemia: a new score system for prediction of the in-hospital mortality risk in patients with SARS-CoV-2 pneumonia. <i>Infezioni in Medicina</i> , 2021, 29, 408-415.	0.7	4
65	Albumin Supplementation Dampens Hypercoagulability in COVID-19: A Preliminary Report. <i>Thrombosis and Haemostasis</i> , 2021, 121, 102-105.	1.8	36
66	Overview of current global CNS morbidity in HIV infection. <i>Journal of the Neurological Sciences</i> , 2021, 429, 118039.	0.3	0
67	Challenges in the Microbiological Diagnosis of Implant-Associated Infections: A Summary of the Current Knowledge. <i>Frontiers in Microbiology</i> , 2021, 12, 750460.	1.5	18
68	Luminescent PLGA Nanoparticles for Delivery of Darunavir to the Brain and Inhibition of Matrix Metalloproteinase-9, a Relevant Therapeutic Target of HIV-Associated Neurological Disorders. <i>ACS Chemical Neuroscience</i> , 2021, 12, 4286-4301.	1.7	9
69	SARS-CoV-2 Among Migrants Recently Arrived in Europe From Low- and Middle-Income Countries: Containment Strategies and Special Features of Management in Reception Centers. <i>Frontiers in Public Health</i> , 2021, 9, 735601.	1.3	2
70	Clinical Effects of Oral Bacteriotherapy on Anal HPV Infection and Related Dysplasia in HIV-Positive MSM: Results from the "HPV in HIV" Trial. <i>Biomedicines</i> , 2021, 9, 1738.	1.4	2
71	Oral Bacteriotherapy Reduces the Occurrence of Chronic Fatigue in COVID-19 Patients. <i>Frontiers in Nutrition</i> , 2021, 8, 756177.	1.6	6
72	Chest computed tomography score, cycle threshold values and secondary infection in predicting COVID-19 mortality. <i>New Microbiologica</i> , 2021, 44, 145-154.	0.1	2

#	ARTICLE	IF	CITATIONS
73	282â€fFollow-up of hospitalized COVID-19 survivors: assessment of short- and long-term cardiovascular sequelae after SARS-CoV-2 infection. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.0	0
74	Physical Activity and HIV: Effects on Fitness Status, Metabolism, Inflammation and Immune-Activation. <i>AIDS and Behavior</i> , 2020, 24, 1042-1050.	1.4	9
75	Latent tuberculosis infection screening in persons newly-diagnosed with HIV infection in Italy: A multicentre study promoted by the Italian Society of Infectious and Tropical Diseases. <i>International Journal of Infectious Diseases</i> , 2020, 92, 62-68.	1.5	13
76	Interplay between male testosterone levels and the risk for subsequent invasive respiratory assistance among COVID-19 patients at hospital admission. <i>Endocrine</i> , 2020, 70, 206-210.	1.1	43
77	Cefiderocol for compassionate use in the treatment of complicated infections caused by extensively and pan-resistant <i>Acinetobacter baumannii</i> . <i>Journal of Global Antimicrobial Resistance</i> , 2020, 23, 292-296.	0.9	41
78	Xerostomia, gustatory and olfactory dysfunctions in patients with COVID-19. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2020, 41, 102721.	0.6	61
79	Retinal involvement and ocular findings in COVID-19 pneumonia patients. <i>Scientific Reports</i> , 2020, 10, 17419.	1.6	65
80	High abundance of genus <i>Prevotella</i> is associated with dysregulation of IFN-I and T cell response in HIV-1-infected patients. <i>Aids</i> , 2020, 34, 1467-1473.	1.0	14
81	False-negative RT-PCR in SARS-CoV-2 disease: experience from an Italian COVID-19 unit. <i>ERJ Open Research</i> , 2020, 6, 00324-2020.	1.1	34
82	The peripheral blood immune cell profile in a teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia. <i>Journal of Neuroimmunology</i> , 2020, 346, 577323.	1.1	21
83	Modulation of Phenylalanine and Tyrosine Metabolism in HIV-1 Infected Patients with Neurocognitive Impairment: Results from a Clinical Trial. <i>Metabolites</i> , 2020, 10, 274.	1.3	7
84	Challenges in the Management of SARS-CoV2 Infection: The Role of Oral Bacteriotherapy as Complementary Therapeutic Strategy to Avoid the Progression of COVID-19. <i>Frontiers in Medicine</i> , 2020, 7, 389.	1.2	152
85	Missed Opportunities of Flu Vaccination in Italian Target Categories: Insights from the Online EPICOVID 19 Survey. <i>Vaccines</i> , 2020, 8, 669.	2.1	8
86	Comparison Between Hospitalized Patients Affected or Not Affected by Coronavirus Disease 2019. <i>Clinical Infectious Diseases</i> , 2020, 72, e1158-e1159.	2.9	7
87	Androgen-deprivation therapy and SARS-Cov-2 infection: the potential double-face role of testosterone. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2020, 11, 204201882096901.	1.4	11
88	Antimicrobial Essential Oil Formulation: Chitosan Coated Nanoemulsions for Nose to Brain Delivery. <i>Pharmaceutics</i> , 2020, 12, 678.	2.0	32
89	Probiotics and COVID-19. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 721-722.	3.7	32
90	Nox2 activation in Covid-19. <i>Redox Biology</i> , 2020, 36, 101655.	3.9	114

#	ARTICLE	IF	CITATIONS
91	Procalcitonin in the Assessment of Ventilator Associated Pneumonia: A Systematic Review. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1323, 103-114.	0.8	14
92	Heart, COVID-19, and echocardiography. <i>Echocardiography</i> , 2020, 37, 1454-1464.	0.3	33
93	Clinical features of patients with type 2 diabetes with and without Covid-19: A case control study (CoViDiab I). <i>Diabetes Research and Clinical Practice</i> , 2020, 169, 108454.	1.1	32
94	The Association between Influenza and Pneumococcal Vaccinations and SARS-Cov-2 Infection: Data from the EPICoVID19 Web-Based Survey. <i>Vaccines</i> , 2020, 8, 471.	2.1	68
95	Analysis of type I IFN response and T cell activation in severe COVID-19/HIV-1 coinfection. <i>Medicine (United States)</i> , 2020, 99, e21803.	0.4	18
96	Anosmia and Ageusia as Predictive Signs of COVID-19 in Healthcare Workers in Italy: A Prospective Case-Control Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 2870.	1.0	27
97	Long-term safety and efficacy of adalimumab in psoriasis: a multicentric study focused on infections (connecting study). <i>Postepy Dermatologii i Alergologii</i> , 2020, 37, 428-434.	0.4	11
98	Is previous influenza-like illness a potential Trojan horse for COVID-19?. <i>Critical Care</i> , 2020, 24, 503.	2.5	10
99	Efficacy of Daptomycin-Containing Regimen for Treatment of Staphylococcal or Enterococcal Vertebral Osteomyelitis: A Prospective Clinical Experience. <i>Antibiotics</i> , 2020, 9, 889.	1.5	3
100	Usefulness of bronchoalveolar lavage in suspect COVID-19 repeatedly negative swab test and interstitial lung disease. <i>Journal of Global Antimicrobial Resistance</i> , 2020, 23, 67-69.	0.9	9
101	Sex-related differences in markers of immune activation in virologically suppressed HIV-infected patients. <i>Biology of Sex Differences</i> , 2020, 11, 23.	1.8	11
102	Type I interferons can be detected in respiratory swabs from SARS-Cov-2 infected patients. <i>Journal of Clinical Virology</i> , 2020, 128, 104450.	1.6	10
103	The need of health policy perspective to protect Healthcare Workers during COVID-19 pandemic. A GRADE rapid review on the N95 respirators effectiveness. <i>PLoS ONE</i> , 2020, 15, e0234025.	1.1	45
104	Is teicoplanin a complementary treatment option for COVID-19? The question remains. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106029.	1.1	41
105	Hypoalbuminemia, Coagulopathy, and Vascular Disease in COVID-19. <i>Circulation Research</i> , 2020, 127, 400-401.	2.0	60
106	Diet Supplementation, Probiotics, and Nutraceuticals in SARS-CoV-2 Infection: A Scoping Review. <i>Nutrients</i> , 2020, 12, 1718.	1.7	155
107	Impact of IFN-Free and IFN-Based Treatment on Blood Myeloid Dendritic Cell, Monocyte, Slan-DC, and Activated T Lymphocyte Dynamics during HCV Infection. <i>Journal of Immunology Research</i> , 2020, 2020, 1-11.	0.9	3
108	Antibacterial Effectiveness of Fecal Water and In Vitro Activity of a Multi-Strain Probiotic Formulation against Multi-Drug Resistant Microorganisms. <i>Microorganisms</i> , 2020, 8, 332.	1.6	2

#	ARTICLE	IF	CITATIONS
109	Effect of low or high doses of low-molecular-weight heparin on thrombin generation and other haemostasis parameters in critically ill patients with COVID-19. <i>British Journal of Haematology</i> , 2020, 190, e214-e218.	1.2	25
110	Chest CT score in COVID-19 patients: correlation with disease severity and short-term prognosis. <i>European Radiology</i> , 2020, 30, 6808-6817.	2.3	530
111	Real world outcomes associated with use of raltegravir in older people living with HIV: results from the 60 months follow-up of the RAL-age cohort. <i>Expert Review of Anti-Infective Therapy</i> , 2020, 18, 485-492.	2.0	4
112	JCPyV NCCR analysis in PML patients with different risk factors: exploring common rearrangements as essential changes for neuropathogenesis. <i>Virology Journal</i> , 2020, 17, 23.	1.4	20
113	Clinical Experience with Ceftazidime-Avibactam for the Treatment of Infections due to Multidrug-Resistant Gram-Negative Bacteria Other than Carbapenem-Resistant Enterobacterales. <i>Antibiotics</i> , 2020, 9, 71.	1.5	68
114	Persistent Systemic Microbial Translocation, Inflammation, and Intestinal Damage During <i>Clostridioides difficile</i> Infection. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofz507.	0.4	17
115	A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 211-213.e4.	1.5	275
116	Key mutations in the C-terminus of the HBV surface glycoprotein correlate with lower HBsAg levels <i>in vivo</i> , hinder HBsAg secretion <i>in vitro</i> and reduce HBsAg structural stability in the setting of HBeAg-negative chronic HBV genotype-D infection. <i>Emerging Microbes and Infections</i> , 2020, 9, 928-939.	3.0	5
117	Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing Enterobacterales Infections: A Multicenter Nationwide Clinical Experience (CEFTABUSE II Study). <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa139.	0.4	49
118	Face Mask Use in the Community for Reducing the Spread of COVID-19: A Systematic Review. <i>Frontiers in Medicine</i> , 2020, 7, 594269.	1.2	42
119	Oral Bacteriotherapy in Patients With COVID-19: A Retrospective Cohort Study. <i>Frontiers in Nutrition</i> , 2020, 7, 613928.	1.6	55
120	Cardiometabolic multimorbidity is associated with a worse Covid-19 prognosis than individual cardiometabolic risk factors: a multicentre retrospective study (CoViDiab II). <i>Cardiovascular Diabetology</i> , 2020, 19, 164.	2.7	90
121	Self-Reported Symptoms of SARS-CoV-2 Infection in a Nonhospitalized Population in Italy: Cross-Sectional Study of the EPICOVID19 Web-Based Survey. <i>JMIR Public Health and Surveillance</i> , 2020, 6, e21866.	1.2	63
122	Monocyte absolute count as a preliminary tool to distinguish between SARS-CoV-2 and influenza A/B infections in patients requiring hospitalization. <i>Infezioni in Medicina</i> , 2020, 28, 534-538.	0.7	2
123	Diagnostic Issues of Asymptomatic Neurosyphilis in HIV-Positive Patients: A Retrospective Study. <i>Brain Sciences</i> , 2019, 9, 278.	1.1	13
124	SAT-190-Specific genetic elements in HBsAg C-terminus profoundly affect HBsAg levels <i>in vivo</i> , hamper HBsAg secretion <i>in vitro</i> and alter HBsAg structural stability in HBeAg-negative chronic HBV genotype D infection. <i>Journal of Hepatology</i> , 2019, 70, e713-e714.	1.8	0
125	HepaDisk – A new quality of life questionnaire for HCV patients. <i>Digestive and Liver Disease</i> , 2019, 51, 1008-1015.	0.4	3
126	Dynamic changes of MMP-9 plasma levels correlate with JCV reactivation and immune activation in natalizumab-treated multiple sclerosis patients. <i>Scientific Reports</i> , 2019, 9, 311.	1.6	12

#	ARTICLE	IF	CITATIONS
127	BioTimer assay as complementary method to vortex-sonication-vortex technique for the microbiological diagnosis of implant associated infections. <i>Scientific Reports</i> , 2019, 9, 7534.	1.6	6
128	Resistance test guided retreatment of HCV infected patients with a previous failure to a NS5A inhibitor-containing regimen: the Italian Vironet C real life experience. <i>Digestive and Liver Disease</i> , 2019, 51, e53-e54.	0.4	0
129	Impact of the 2017 measles outbreak on the emergency care system of a large tertiary-care teaching hospital in Italy: a retrospective analysis. <i>European Journal of Public Health</i> , 2019, 29, 966-971.	0.1	8
130	Daclatasvir, sofosbuvir with or without ribavirin for 24 weeks in hepatitis C genotype 3 cirrhosis: A real-life study. <i>Annals of Hepatology</i> , 2019, 18, 434-438.	0.6	8
131	Key mutations in HBsAg C-terminus correlate with lower HBsAg levels in vivo, hinder HBsAg release in vitro and affect HBsAg structural stability in HBeAg-negative chronic HBV genotype D infection. <i>Digestive and Liver Disease</i> , 2019, 51, e60.	0.4	0
132	In-Vitro Evaluation of Different Antimicrobial Combinations with and without Colistin Against Carbapenem-Resistant <i>Acinetobacter Baumannii</i> . <i>Molecules</i> , 2019, 24, 886.	1.7	12
133	A snapshot of virological presentation and outcome of immunosuppression-driven HBV reactivation from real clinical practice: Evidence of a relevant risk of death and evolution from silent to chronic infection. <i>Journal of Viral Hepatitis</i> , 2019, 26, 846-855.	1.0	9
134	Characterization of QuantiFERON-TB-Plus results in latent tuberculosis infected patients with or without immune-mediated inflammatory diseases. <i>Journal of Infection</i> , 2019, 79, 15-23.	1.7	16
135	Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice. <i>Virus Genes</i> , 2019, 55, 290-297.	0.7	0
136	The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, e17-e21.	0.9	2
137	Increased IL-17 and/or IFN- γ producing T-cell subsets in gut mucosa of long-term-treated HIV-1-infected women. <i>Aids</i> , 2019, 33, 627-636.	1.0	7
138	Italian consensus recommendations for the management of hepatitis C infection in patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2019, 29, 895-902.	0.9	9
139	Ceftolozane/tazobactam for the treatment of serious <i>Pseudomonas aeruginosa</i> infections: a multicentre nationwide clinical experience. <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 408-415.	1.1	120
140	Reactivation of Hepatitis B Virus With Immune-Escape Mutations After Ocrelizumab Treatment for Multiple Sclerosis. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofy356.	0.4	54
141	Diagnostic performance in active TB of QFT-Plus assay and co-expression of CD25/CD134 in response to new antigens of <i>Mycobacterium tuberculosis</i> . <i>Medical Microbiology and Immunology</i> , 2019, 208, 171-183.	2.6	6
142	Epidemiology and Microbiology of Skin and Soft Tissue Infections: Preliminary Results of a National Registry. <i>Journal of Chemotherapy</i> , 2019, 31, 9-14.	0.7	14
143	Myeloid and lymphoid activation markers in AIDS and non-AIDS presenters. <i>Immunobiology</i> , 2019, 224, 231-241.	0.8	8
144	Aseptic meningitis induced by intravenous immunoglobulins in a child with acute Epstein-Barr virus infection and thrombocytopenia. <i>Infezioni in Medicina</i> , 2019, 27, 194-197.	0.7	4

#	ARTICLE	IF	CITATIONS
145	<i>In vitro</i> effect of antiretroviral drugs on cultured primary astrocytes: analysis of neurotoxicity and matrix metalloproteinase inhibition. <i>Journal of Neurochemistry</i> , 2018, 144, 271-284.	2.1	24
146	Role of Double-Carbapenem Regimen in the Treatment of Infections due to Carbapenemase Producing Carbapenem-Resistant <i>Enterobacteriaceae</i>: A Single-Center, Observational Study. <i>BioMed Research International</i> , 2018, 2018, 1-8.	0.9	19
147	Genetic divergence of HIV-1 B subtype in Italy over the years 2003â€“2016 and impact on CTL escape prevalence. <i>Scientific Reports</i> , 2018, 8, 15739.	1.6	2
148	Persistent high plasma levels of sCD163 and sCD14 in adult patients with measles virus infection. <i>PLoS ONE</i> , 2018, 13, e0198174.	1.1	8
149	Changes in T cell effector functions over an 8-year period with TNF antagonists in patients with chronic inflammatory rheumatic diseases. <i>Scientific Reports</i> , 2018, 8, 7881.	1.6	8
150	JC Virus-DNA Detection Is Associated with CD8 Effector Accumulation in Peripheral Blood of Patients with Multiple Sclerosis under Natalizumab Treatment, Independently from JC Virus Serostatus. <i>BioMed Research International</i> , 2018, 2018, 1-10.	0.9	9
151	Intracranial tuberculous mass lesions treated with thalidomide in an immunocompetent child from a low tuberculosis endemic country. <i>Medicine (United States)</i> , 2018, 97, e11186.	0.4	9
152	Key mutational patterns in HBsAg C-terminus profoundly affect HBsAg levels in HBeAg-negative chronic HBV genotype D infection. <i>Journal of Hepatology</i> , 2018, 68, S492-S493.	1.8	0
153	Systemic adipokines, hepatokines and interleukin-6 in HCV-monoinfected and HCV/HIV coinfecting patients treated with direct antiviral agents (DAAs). <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2018, 42, e45-e48.	0.7	1
154	Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment. <i>Journal of Clinical Virology</i> , 2018, 104, 61-64.	1.6	19
155	HDV Can Constrain HBV Genetic Evolution in HBsAg: Implications for the Identification of Innovative Pharmacological Targets. <i>Viruses</i> , 2018, 10, 363.	1.5	4
156	Trend of estimated glomerular filtration rate during ombitasvir/paritaprevir/ritonavir plus dasabuvir Â± ribavirin in HIV/HCV co-infected patients. <i>PLoS ONE</i> , 2018, 13, e0192627.	1.1	6
157	Detection of biofilm-associated implant pathogens in cardiac device infections: High sensitivity of sonication fluid culture even in the presence of antimicrobials. <i>Journal of Global Infectious Diseases</i> , 2018, 10, 74.	0.2	5
158	Prise en charge de lâ€™infection par le virus de lâ€™hÃ©patite B chez les patients atteints de polyarthrite rhumatoïde: conférence de consensus italienne. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2018, 85, 115-120.	0.0	0
159	Multiclass <sc>HCV</sc> resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. <i>Liver International</i> , 2017, 37, 514-528.	1.9	84
160	Italian consensus Guidelines for the management of hepatitis B virus infections in patients with rheumatoid arthritis. <i>Joint Bone Spine</i> , 2017, 84, 525-530.	0.8	15
161	Case report: human papilloma virus type 120-related papillomatosis mimicking laryngeal carcinoma. <i>Infection</i> , 2017, 45, 709-713.	2.3	1
162	Active HCV infection is associated with increased circulating levels of interferon-gamma (IFN-Î³)-inducible protein-10 (IP-10), soluble CD163 and inflammatory monocytes regardless of liver fibrosis and HIV coinfection. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2017, 41, 644-655.	0.7	22

#	ARTICLE	IF	CITATIONS
163	In vitro evaluation of different antimicrobial combinations against carbapenemase-producing <i>Klebsiella pneumoniae</i> : the activity of the double-carbapenem regimen is related to meropenem MIC value. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1981-1984.	1.3	30
164	Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus. <i>Clinical Microbiology and Infection</i> , 2017, 23, 267.e1-267.e4.	2.8	11
165	HCV and diabetes: towards a "Sustained" glycaemic improvement after treatment with DAAs? Authors' reply. <i>Clinical Microbiology and Infection</i> , 2017, 23, 344.	2.8	0
166	Dynamics and phylogenetic relationships of HIV-1 transmitted drug resistance according to subtype in Italy over the years 2000-14. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2837-2845.	1.3	15
167	Comparative Evaluation of Subtyping Tools for Surveillance of Newly Emerging HIV-1 Strains. <i>Journal of Clinical Microbiology</i> , 2017, 55, 2827-2837.	1.8	18
168	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 427-434.	3.7	15
169	Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated With Incident and Prevalent Type 2 Diabetes in Persons Living With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, 465-471.	0.9	4
170	Immunological diagnosis as an adjunctive tool for an early diagnosis of tuberculous meningitis of an immune competent child in a low tuberculosis endemic country: a case report. <i>BMC Research Notes</i> , 2017, 10, 123.	0.6	4
171	Double-carbapenem regimen, alone or in combination with colistin, in the treatment of infections caused by carbapenem-resistant <i>Klebsiella pneumoniae</i> (CR-Kp). <i>Journal of Infection</i> , 2017, 74, 103-106.	1.7	38
172	Diplopia as isolated presentation of varicella zoster central nervous system reactivation. <i>Journal of NeuroVirology</i> , 2017, 23, 621-624.	1.0	1
173	Changes in inflammatory biomarkers in HCV-infected patients undergoing direct acting antiviral-containing regimens with or without interferon. <i>PLoS ONE</i> , 2017, 12, e0179400.	1.1	40
174	Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial. <i>PLoS ONE</i> , 2017, 12, e0187393.	1.1	11
175	Clinical and in vitro efficacy of colistin plus vancomycin and rifampin against colistin-resistant <i>Acinetobacter baumannii</i> causing ventilator-associated pneumonia. <i>New Microbiologica</i> , 2017, 40, 205-207.	0.1	8
176	Recommendations for the management of pulmonary fungal infections in patients with rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 1018-1028.	0.4	8
177	The role of interferon-gamma release assays in predicting the emergence of active tuberculosis in the setting of biological treatment: a case report and review of the literature. <i>Clinical Rheumatology</i> , 2016, 35, 1383-1388.	1.0	7
178	Liver Fibrosis in HCV Monoinfected and HIV/HCV Coinfected Patients: Dysregulation of Matrix Metalloproteinases (MMPs) and Their Tissue Inhibitors TIMPs and Effect of HCV Protease Inhibitors. <i>International Journal of Molecular Sciences</i> , 2016, 17, 455.	1.8	30
179	Higher Levels of Osteoprotegerin and Immune Activation/Immunosenescence Markers Are Correlated with Concomitant Bone and Endovascular Damage in HIV-Suppressed Patients. <i>PLoS ONE</i> , 2016, 11, e0149601.	1.1	14
180	Discontinuation of Initial Antiretroviral Therapy in Clinical Practice. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 263-271.	0.9	39

#	ARTICLE	IF	CITATIONS
181	Severe Bloodstream Infection due to KPC-Producer E coli in a Renal Transplant Recipient Treated With the Double-Carbapenem Regimen and Analysis of In Vitro Synergy Testing. <i>Medicine (United States)</i> , 2016, 95, e2243.	0.4	13
182	Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients with HIV/HCV Co-Infection: Results of an Italian Compassionate Use Program. <i>Clinical Infectious Diseases</i> , 2016, 64, ciw846.	2.9	8
183	Herpes virus reactivation after initiation of interferon-free antiviral agents in HIV+HCV-coinfected subjects: a new immune restoration disease?. <i>Antiviral Therapy</i> , 2016, 21, 739-742.	0.6	5
184	Immunosuppression-driven HBV reactivation in patients with resolved HBV infection correlates with a relevant risk of death and with evolution towards active chronic infection. <i>Digestive and Liver Disease</i> , 2016, 48, e18-e19.	0.4	0
185	Nursing home residence is associated with spread of <i>Clostridium difficile</i> ribotype O27 in central Italy. <i>Journal of Hospital Infection</i> , 2016, 94, 201-203.	1.4	4
186	Pregnancy outcomes and cytomegalovirus DNAemia in HIV-infected pregnant women with CMV. <i>Clinical Microbiology and Infection</i> , 2016, 22, 818-820.	2.8	2
187	Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA. <i>Journal of Clinical Virology</i> , 2016, 82, 94-100.	1.6	35
188	HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 739-750.	1.3	13
189	Rapid decline of fasting glucose in HCV diabetic patients treated with direct-acting antiviral agents. <i>Clinical Microbiology and Infection</i> , 2016, 22, 462.e1-462.e3.	2.8	77
190	Impact of switching from lopinavir/ritonavir to boosted and un-boosted atazanavir on glucose metabolism: the ATAZANAVIR & GLUCOSE metabolism (ATAGLU) study. <i>International Journal of STD and AIDS</i> , 2016, 27, 638-643.	0.5	5
191	Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort. <i>Clinical Microbiology and Infection</i> , 2016, 22, 288.e1-288.e8.	2.8	33
192	Bactericidal and synergistic activity of double-carbapenem regimen for infections caused by carbapenemase-producing <i>Klebsiella pneumoniae</i> . <i>Clinical Microbiology and Infection</i> , 2016, 22, 147-153.	2.8	47
193	Treatment of latent tuberculosis infection induces changes in multifunctional <i>Mycobacterium tuberculosis</i> -specific CD4+ T cells. <i>Medical Microbiology and Immunology</i> , 2016, 205, 37-45.	2.6	5
194	Natalizumab Affects T-Cell Phenotype in Multiple Sclerosis: Implications for JCV Reactivation. <i>PLoS ONE</i> , 2016, 11, e0160277.	1.1	21
195	Long-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical Practice. <i>PLoS ONE</i> , 2016, 11, e0160761.	1.1	5
196	Blood Myeloid Dendritic Cells and slanDC in Antiretroviral Therapy- Suppressed HIV-Infected Patients. <i>Current HIV Research</i> , 2016, 14, 331-339.	0.2	6
197	Archetype and Rearranged Non-coding Control Regions in Urothelial Bladder Carcinoma of Immunocompetent Individuals. <i>Cancer Genomics and Proteomics</i> , 2016, 13, 499-510.	1.0	5
198	Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation Cohort. <i>PLoS ONE</i> , 2016, 11, e0156360.	1.1	0

#	ARTICLE	IF	CITATIONS
199	Pseudo-outbreak of <i>Mycobacterium gordonae</i> in a teaching hospital: importance of strictly following decontamination procedures and emerging issues concerning sterilization. <i>New Microbiologica</i> , 2016, 39, 25-34.	0.1	13
200	Incidence and factors associated with the risk of sexually transmitted diseases in HIV-infected people seen for care in Italy: data from the Cona Foundation cohort. <i>HIV Medicine</i> , 2015, 16, 412-420.	1.0	4
201	Large Nosocomial Outbreak Associated with a Norwegian Scabies Index Case Undergoing TNF- α Inhibitor Treatment: Management and Control. <i>Infection Control and Hospital Epidemiology</i> , 2015, 36, 1358-1360.	1.0	16
202	Good prenatal detection rate of major birth defects in HIV-infected pregnant women in Italy. <i>Prenatal Diagnosis</i> , 2015, 35, 1374-1378.	1.1	3
203	Detecting latent tuberculosis in compromised patients. <i>Current Opinion in Infectious Diseases</i> , 2015, 28, 275-282.	1.3	13
204	Evaluation of the Prognostic Value of Impaired Renal Function on Clinical Progression in a Large Cohort of HIV-Infected People Seen for Care in Italy. <i>PLoS ONE</i> , 2015, 10, e0124252.	1.1	7
205	Recent Transmission Clustering of HIV-1 CRF17_BF Strains Characterized by NNRTI-Related Mutations among Newly Diagnosed Men in Central Italy. <i>PLoS ONE</i> , 2015, 10, e0135325.	1.1	21
206	Multifunctional Analysis of CD4 ⁺ T-Cell Response as Immune-Based Model for Tuberculosis Detection. <i>Journal of Immunology Research</i> , 2015, 2015, 1-10.	0.9	21
207	Therapeutic strategy for pandrug-resistant <i>Klebsiella pneumoniae</i> severe infections: short-course treatment with colistin increases the in vivo and in vitro activity of double carbapenem regimen. <i>International Journal of Infectious Diseases</i> , 2015, 33, 132-134.	1.5	37
208	CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study. <i>Lancet HIV</i> , 2015, 2, e98-e106.	2.1	249
209	Genotypic Tropism Testing in HIV-1 Proviral DNA Can Provide Useful Information at Low-Level Viremia. <i>Journal of Clinical Microbiology</i> , 2015, 53, 2935-2941.	1.8	6
210	Atypical presentation of crusted (Norwegian) scabies. <i>Infection</i> , 2015, 43, 623-624.	2.3	9
211	Role of Sonication in the Microbiological Diagnosis of Implant-Associated Infections: Beyond the Orthopedic Prosthesis. <i>Advances in Experimental Medicine and Biology</i> , 2015, 897, 85-102.	0.8	28
212	Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression. <i>Hepatology</i> , 2015, 61, 823-833.	3.6	109
213	Undetectable HCV RNA at treatment week 8 results in high sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program. <i>Journal of Viral Hepatitis</i> , 2015, 22, 469-480.	1.0	9
214	Determinants of use of the fixed dose combination emtricitabine/rilpivirine/tenofovir (Eviplera) in HIV-infected persons receiving care in Italy. <i>Journal of the International AIDS Society</i> , 2014, 17, 19775.	1.2	0
215	Immune Activation, Immunosenescence, and Osteoprotegerin as Markers of Endothelial Dysfunction in Subclinical HIV-Associated Atherosclerosis. <i>Mediators of Inflammation</i> , 2014, 2014, 1-8.	1.4	18
216	Molecular Mechanisms of Liver Fibrosis in HIV/HCV Coinfection. <i>International Journal of Molecular Sciences</i> , 2014, 15, 9184-9208.	1.8	80

#	ARTICLE	IF	CITATIONS
217	Taming HIV-Related Inflammation with Physical Activity: A Matter of Timing. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 936-944.	0.5	45
218	Long-term IFN- γ and IL-2 response for detection of latent tuberculosis infection in healthcare workers with discordant immunologic results. <i>Journal of Immunological Methods</i> , 2014, 414, 51-57.	0.6	12
219	Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3085-3094.	1.3	6
220	Synergistic activity and effectiveness of a double-carbapenem regimen in pandrug-resistant <i>Klebsiella pneumoniae</i> bloodstream infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1718-1720.	1.3	56
221	<i>Legionella pneumophila</i> pneumonia during telaprevir-based triple therapy for HCV chronic hepatitis. <i>Infection</i> , 2014, 42, 225-226.	2.3	2
222	Recovery of Interleukin-17 Production from Interleukin-15-Stimulated CD4+ Mononuclear Cells in HIV-1-Infected Patients with Sustained Viral Suppression. <i>Journal of Interferon and Cytokine Research</i> , 2014, 34, 35-40.	0.5	4
223	Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 735-741.	1.3	16
224	Atazanavir and lopinavir profile in pregnant women with HIV: tolerability, activity and pregnancy outcomes in an observational national study. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1377-1384.	1.3	13
225	Multi-functional flow cytometry analysis of CD4+ T cells as an immune biomarker for latent tuberculosis status in patients treated with tumour necrosis factor (TNF) antagonists. <i>Clinical and Experimental Immunology</i> , 2014, 176, 410-417.	1.1	19
226	HBsAg genetic elements critical for immune escape correlates with HBV reactivation upon immunosuppression. <i>Digestive and Liver Disease</i> , 2014, 46, e11.	0.4	2
227	Reconstitution of Intestinal CD4 and Th17 T Cells in Antiretroviral Therapy Suppressed HIV-Infected Subjects: Implication for Residual Immune Activation from the Results of a Clinical Trial. <i>PLoS ONE</i> , 2014, 9, e109791.	1.1	26
228	Interferon- γ release assay in HIV-infected patients with active tuberculosis: impact of antituberculous drugs on host immune response. <i>New Microbiologica</i> , 2014, 37, 153-61.	0.1	8
229	Extraviral modulation of immune response by an NRTI-sparing antiretroviral regimen including darunavir and maraviroc. <i>New Microbiologica</i> , 2014, 37, 225-9.	0.1	3
230	Sonication technique improves microbiological diagnosis in patients treated with antibiotics before surgery for prosthetic joint infections. <i>New Microbiologica</i> , 2014, 37, 321-8.	0.1	35
231	<i>Mycobacterial Interferon-γ Release Variations During Longterm Treatment with Tumor Necrosis Factor Blockers: Lack of Correlation with Clinical Outcome.</i> <i>Journal of Rheumatology</i> , 2013, 40, 157-165.	1.0	30
232	Postpartum fever in the presence of a fibroid: <i>Sphingomonas paucimobilis</i> sepsis associated with pyomyoma. <i>BMC Infectious Diseases</i> , 2013, 13, 574.	1.3	17
233	Late onset invasive pneumococcal disease in a liver transplanted patient: beyond the <sc>A</sc>ustrian syndrome. <i>Transplant Infectious Disease</i> , 2013, 15, E111-4.	0.7	11
234	Interferon- γ release assay for tuberculosis in patients with psoriasis treated with tumour necrosis factor antagonists: in vivo and in vitro analysis. <i>British Journal of Dermatology</i> , 2013, 169, 1133-1140.	1.4	22

#	ARTICLE	IF	CITATIONS
235	Sonication of Explanted Cardiac Implants Improves Microbial Detection in Cardiac Device Infections. <i>Journal of Clinical Microbiology</i> , 2013, 51, 496-502.	1.8	38
236	Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: a cohort study. <i>BMC Infectious Diseases</i> , 2013, 13, 471.	1.3	68
237	Dendritic cells in blood and urine samples from bladder cancer patients undergoing BCG immunotherapy. <i>Archivio Italiano Di Urologia Andrologia</i> , 2013, 85, 157.	0.4	16
238	Hepatitis E Virus Genotype 4 Outbreak, Italy, 2011. <i>Emerging Infectious Diseases</i> , 2013, 19, 110-114.	2.0	90
239	The potential impact of routine testing of individuals with HIV indicator diseases in order to prevent late HIV diagnosis. <i>BMC Infectious Diseases</i> , 2013, 13, 473.	1.3	38
240	Early Atherosclerosis in HIV Infected Subjects on Suppressive Antiretroviral Treatment: Role of Osteoprotegerin. <i>Isrn Aids</i> , 2013, 2013, 1-6.	2.5	6
241	Study of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) carriage in a population of HIV-negative migrants and HIV-infected patients attending an outpatient clinic in Rome. <i>Annali Di Igiene: Medicina Preventiva E Di Comunita</i> , 2013, 25, 99-107.	0.5	8
242	Hepatitis B reactivation despite entecavir prophylaxis in a patient with chronic lymphocytic leukaemia receiving bendamustine. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 510-511.	1.3	5
243	<i>Bartonella henselae</i> Infection Presenting With Ocular and Hepatosplenic Manifestations in an Immunocompetent Child. <i>Pediatric Infectious Disease Journal</i> , 2012, 31, 882-883.	1.1	2
244	Serial interferon- γ release assays for screening and monitoring of tuberculosis infection during treatment with biologic agents. <i>Clinical Rheumatology</i> , 2012, 31, 1567-1575.	1.0	29
245	The role of IL-15 in challenging Acquired Immunodeficiency Syndrome. <i>Cytokine</i> , 2012, 57, 54-60.	1.4	6
246	Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy. <i>American Journal of Hematology</i> , 2012, 87, 749-753.	2.0	24
247	Significant coronary stenosis detected by coronary computed angiography in asymptomatic HIV infected subjects. <i>Journal of Infection</i> , 2012, 64, 82-88.	1.7	24
248	Pandemic influenza H1N1, legionellosis, splenic rupture, and vascular thrombosis. <i>Journal of Postgraduate Medicine</i> , 2012, 58, 228-229.	0.2	6
249	Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011. <i>New Microbiologica</i> , 2012, 35, 113-59.	0.1	25
250	In Vitro Downregulation of Matrix Metalloproteinase-9 in Rat Glial Cells by CCR5 Antagonist Maraviroc: Therapeutic Implication for HIV Brain Infection. <i>PLoS ONE</i> , 2011, 6, e28499.	1.1	22
251	HIV Persistence in the Gut Mucosa of HIV-Infected Subjects Undergoing Antiretroviral Therapy Correlates with Immune Activation and Increased Levels of LPS. <i>Current HIV Research</i> , 2011, 9, 148-153.	0.2	68
252	In vitro effect of anti-human immunodeficiency virus CCR5 antagonist maraviroc on chemotactic activity of monocytes, macrophages and dendritic cells. <i>Clinical and Experimental Immunology</i> , 2011, 166, 184-190.	1.1	45

#	ARTICLE	IF	CITATIONS
253	Influence of previous tuberculin skin test on serial IFN- γ release assays. <i>Tuberculosis</i> , 2011, 91, 322-326.	0.8	27
254	Development of Buffalo Hump in the course of antiretroviral therapy including raltegravir and unboosted atazanavir: a case report and review of the literature. <i>Journal of Medical Case Reports</i> , 2011, 5, 70.	0.4	9
255	Adherence and Genotypic Drug Resistance Mutations in HIV-1-Infected Patients Failing Current Antiretroviral Therapy. <i>Journal of Chemotherapy</i> , 2011, 23, 24-27.	0.7	4
256	Severe and Persistent Depletion of Circulating Plasmacytoid Dendritic Cells in Patients with 2009 Pandemic H1N1 Infection. <i>PLoS ONE</i> , 2011, 6, e19872.	1.1	31
257	Current trends in management of hepatitis B virus reactivation in the biologic therapy era. <i>World Journal of Gastroenterology</i> , 2011, 17, 3881.	1.4	51
258	Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. <i>New Microbiologica</i> , 2011, 34, 109-46.	0.1	20
259	Downregulation of Leukocyte Migration After Treatment With CCR5 Antagonist Maraviroc. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 54, e13-e14.	0.9	10
260	Antiviral treatment including entecavir plus tenofovir disoproxil fumarate for HBV reactivation following a rituximab-based regimen. <i>Antiviral Therapy</i> , 2010, 15, 929-932.	0.6	17
261	Diagnostic and therapeutic approach in a rare case of primary bilateral adrenal tuberculosis. <i>Journal of Medical Microbiology</i> , 2010, 59, 1527-1529.	0.7	6
262	Pacemaker Lead Endocarditis Due to Multidrug-Resistant <i>Corynebacterium striatum</i> Detected with Sonication of the Device. <i>Journal of Clinical Microbiology</i> , 2010, 48, 4669-4671.	1.8	34
263	Primary retroperitoneal abscesses due to <i>Rhodococcus equi</i> in a patient with severe nephrotic syndrome: successful antibiotic treatment with linezolid and tigecycline. <i>International Journal of Infectious Diseases</i> , 2010, 14, e533-e535.	1.5	11
264	The role of HIV-DNA testing in clinical practice. <i>New Microbiologica</i> , 2010, 33, 1-11.	0.1	19
265	Pulmonary embolism and acute cytomegalovirus infection in an immunocompetent patient. <i>Infezioni in Medicina</i> , 2010, 18, 270-2.	0.7	2
266	In Vivo Release of Alpha-Defensins in Plasma, Neutrophils and CD8 T Lymphocytes of Patients with HIV Infection. <i>Current HIV Research</i> , 2009, 7, 650-655.	0.2	13
267	Case 11-2009: A Man with Fever, Headache, Rash, and Vomiting. <i>New England Journal of Medicine</i> , 2009, 361, 312-314.	13.9	3
268	Lack of community-associated MRSA in Rome. <i>Journal of Hospital Infection</i> , 2009, 71, 374-376.	1.4	6
269	Increased carotid intima media thickness is associated with depletion of circulating myeloid dendritic cells in HIV-infected patients on suppressive antiretroviral treatment. <i>Atherosclerosis</i> , 2009, 204, e1-e3.	0.4	11
270	The Absence of HIV Mutations in Cerebrospinal Fluid and in Peripheral Blood Mononuclear Cells During a Regimen Containing Trizivir Plus Tenofovir. <i>Journal of Chemotherapy</i> , 2009, 21, 455-457.	0.7	1

#	ARTICLE	IF	CITATIONS
271	In Vivo and In Vitro Effects of Antituberculosis Treatment on Mycobacterial Interferon- γ T Cell Response. PLoS ONE, 2009, 4, e5187.	1.1	48
272	Atypical Localization of Leishmaniasis in an Intestinal Polyp. Infection, 2008, 36, 187-188.	2.3	4
273	QuantiFERON-TB Gold and selected region of difference 1 peptide-based assays for the detection of Mycobacterium tuberculosis infection in a cohort of patients enrolled with suspected tuberculosis. Diagnostic Microbiology and Infectious Disease, 2008, 62, 395-401.	0.8	6
274	Urolithiasis Under Atazanavir Boosted and Tenofovir Therapy: A Case Report. Journal of Chemotherapy, 2008, 20, 143-144.	0.7	5
275	Plasmacytoid Dendritic Cells Count in Antiretroviral-Treated Patients is Predictive of HIV Load Control Independent of CD4+ T-Cell Count. Current HIV Research, 2008, 6, 19-27.	0.2	23
276	Simplified Maintenance Therapy with Abacavir/Lamivudine/Zidovudine plus Tenofovir After Sustained HIV Load Suppression: Four Years of Follow-up. HIV Clinical Trials, 2007, 8, 182-188.	2.0	6
277	Antiretroviral therapy inhibits matrix metalloproteinase-9 from blood mononuclear cells of HIV-infected patients. Aids, 2007, 21, 677-684.	1.0	34
278	Matrix metalloproteinase dysregulation in HIV infection: implications for therapeutic strategies. Trends in Molecular Medicine, 2007, 13, 449-459.	3.5	71
279	Characterization of circulating blood dendritic cell subsets DC123+ (Lymphoid) and DC11C+ (myeloid) in prostate adenocarcinoma patients. Prostate, 2007, 67, 1-7.	1.2	37
280	Cross-presentation of caspase-cleaved apoptotic self antigens in HIV infection. Nature Medicine, 2007, 13, 1431-1439.	15.2	74
281	Tuberculosis and Legionella pneumophila pneumonia in a patient receiving anti-tumour necrosis factor- α (anti-TNF- α) treatment. Clinical Microbiology and Infection, 2007, 13, 1036-1037.	2.8	19
282	Central role of interleukin-15 in human immunodeficiency virus (HIV)-infected patients with visceral leishmaniasis. Acta Tropica, 2006, 99, 83-87.	0.9	16
283	Circulating dendritic cells and interferon-alpha production in patients with tuberculosis: correlation with clinical outcome and treatment response. Clinical and Experimental Immunology, 2006, 143, 329-337.	1.1	50
284	Interleukin-15 enhances the secretion of IFN- γ and CC chemokines by natural killer cells from HIV viremic and aviremic patients. Immunology Letters, 2006, 103, 192-195.	1.1	19
285	Abdominal aortic mycotic aneurysm, psoas abscess, and aorto-bisiliac graft infection due to Salmonella typhimurium. Journal of Infection and Chemotherapy, 2006, 12, 52.	0.8	0
286	HIV protease inhibitor therapy reverses neutrophil apoptosis in AIDS patients by direct calpain inhibition. Apoptosis: an International Journal on Programmed Cell Death, 2006, 11, 781-787.	2.2	20
287	Evolving simplified treatment strategies for HIV infection: the role of a single-class quadruple-nucleoside/nucleotide regimen of trizivir and tenofovir. Expert Opinion on Pharmacotherapy, 2006, 7, 2233-2241.	0.9	2
288	Switching from protease inhibitors to a single-class regimen of abacavir/lamivudine/zidovudine plus tenofovir in patients with HIV load suppression. Aids, 2005, 19, 841-842.	1.0	6

#	ARTICLE	IF	CITATIONS
289	Abdominal aortic mycotic aneurysm, psoas abscess, and aorto-bisiliac graft infection due to <i>Salmonella typhimurium</i> . <i>Journal of Infection and Chemotherapy</i> , 2005, 11, 297-299.	0.8	5
290	Rapid identification of <i>Bartonella henselae</i> by real-time polymerase chain reaction in a patient with cat scratch disease. <i>Diagnostic Microbiology and Infectious Disease</i> , 2005, 53, 75-77.	0.8	9
291	Interleukin-15 production by monocyte-derived dendritic cells and T cell proliferation in HIV-infected patients with discordant response to highly active antiretroviral therapy. <i>Clinical and Experimental Immunology</i> , 2004, 135, 280-285.	1.1	9
292	Anti-HIV drugs decrease the expression of matrix metalloproteinases in astrocytes and microglia. <i>Brain</i> , 2004, 127, 398-407.	3.7	52
293	Interleukin-15 modulates interferon- γ and β -chemokine production in patients with HIV infection: implications for immune-based therapy. <i>Cytokine</i> , 2004, 25, 283-290.	1.4	18
294	Teaching tired T cells to fight HIV: time to test IL-15 for immunotherapy?. <i>Trends in Immunology</i> , 2004, 25, 121-125.	2.9	39
295	New Case of Acute Hepatitis Following the Consumption of Shou Wu Pian, a Chinese Herbal Product Derived from <i>Polygonum multiflorum</i> . <i>Annals of Internal Medicine</i> , 2004, 140, W-30.	2.0	74
296	Anti-apoptotic effect of HIV protease inhibitors via direct inhibition of calpain. <i>Biochemical Pharmacology</i> , 2003, 66, 1505-1512.	2.0	36
297	Effect of Limonin and Nomilin on HIV-1 Replication on Infected Human Mononuclear Cells. <i>Planta Medica</i> , 2003, 69, 910-913.	0.7	97
298	Matrix Metalloproteinase-9 and Tissue Inhibitors of Matrix Metalloproteinase-1 in Plasma of Patients Co-Infected with HCV and HIV. <i>HIV Clinical Trials</i> , 2002, 3, 310-315.	2.0	27
299	In vitro Anti-HIV Activity of Oleanolic Acid on Infected Human Mononuclear Cells. <i>Planta Medica</i> , 2002, 68, 111-114.	0.7	95
300	Interleukin-15 in HIV infection: immunological and virological interactions in antiretroviral-naïve and -treated patients. <i>Aids</i> , 2002, 16, 181-188.	1.0	56
301	Discordant response to antiretroviral therapy. <i>Aids</i> , 2002, 16, 1877-1885.	1.0	18
302	Circulating Levels of Interleukin-7 in Antiretroviral-Naïve and Highly Active Antiretroviral Therapy-Treated HIV-Infected Patients. <i>HIV Clinical Trials</i> , 2001, 2, 108-112.	2.0	37
303	Primary effusion lymphoma in HIV-infected patients with multicentric Castleman's disease. <i>Journal of Pathology</i> , 2001, 193, 200-209.	2.1	47
304	Rhabdomyolysis after cerivastatin/gemfibrozil therapy in an HIV-infected patient with protease inhibitor-related hyperlipidemia. <i>Aids</i> , 2001, 15, 820-821.	1.0	35
305	Relapsing and disseminated VZV infection associated with post-zoster neuralgia in an HIV-infected patient. <i>Journal of Headache and Pain</i> , 2000, 1, 131-132.	2.5	0
306	CASE REPORT: Long-term Remission of Human Immunodeficiency Virus-associated Visceral Leishmaniasis after Initiation of Potent Combination Antiretroviral Treatment: Report of Two Cases. <i>Journal of Infection</i> , 2000, 40, 94-96.	1.7	13

#	ARTICLE	IF	CITATIONS
307	Interleukin-15 enhances neutrophil functional activity in patients with human immunodeficiency virus infection. <i>Blood</i> , 2000, 96, 1979-1984.	0.6	42
308	Increased activity of matrix metalloproteinases in the cerebrospinal fluid of patients with HIV-associated neurological diseases. <i>Journal of NeuroVirology</i> , 2000, 6, 156-163.	1.0	75
309	Ex Vivo and In Vitro Effect of Human Immunodeficiency Virus Protease Inhibitors on Neutrophil Apoptosis. <i>Journal of Infectious Diseases</i> , 2000, 182, 1536-1539.	1.9	34
310	Changes in Circulating Levels of Soluble Cell Adhesion Molecules Following Highly Active Antiretroviral Treatment of HIV-1-Infected Patients. <i>Clinical Immunology</i> , 2000, 95, 212-217.	1.4	17
311	Interleukin-15 enhances neutrophil functional activity in patients with human immunodeficiency virus infection. <i>Blood</i> , 2000, 96, 1979-1984.	0.6	12
312	Reduction of IFN-g and IL-2 production by peripheral lymphocytes of HIV-exposed seronegative subjects. <i>Aids</i> , 1999, 13, 1333-1336.	1.0	13
313	Search for an antibody profile of <i>Rhodococcus equi</i> infection in AIDS patients despite the diversity of isolates and patient immune dysfunction. <i>Microbes and Infection</i> , 1999, 1, 663-670.	1.0	7
314	Reversal of AIDS dementia after combination therapy with stavudine, lamivudine, and nelfinavir. <i>Journal of Neurology</i> , 1999, 246, 972-973.	1.8	4
315	Human herpesvirus-8 in lymphomatous and nonlymphomatous body cavity effusions developing in Kaposi's sarcoma and multicentric Castleman's disease. <i>Annals of Diagnostic Pathology</i> , 1999, 3, 357-363.	0.6	29
316	Improvement in neutrophil and monocyte function during highly active antiretroviral treatment of HIV-1-infected patients. <i>Aids</i> , 1999, 13, 883-890.	1.0	72
317	<i>Rhodococcus equi</i> infection of monocytes/macrophages from human immunodeficiency virus (HIV)-infected patients and healthy individuals: evaluation of intracellular killing and nitric oxide production. <i>FEMS Immunology and Medical Microbiology</i> , 1998, 21, 11-17.	2.7	8
318	Chemokine profiles in the cerebrospinal fluid (CSF) during the course of pyogenic and tuberculous meningitis. <i>Clinical and Experimental Immunology</i> , 1998, 114, 210-214.	1.1	50
319	Autoimmune T-Cell Response to the CD4 Molecule in HIV-Infected Patients. <i>Viral Immunology</i> , 1998, 11, 9-17.	0.6	17
320	In vitro production of tumor necrosis factor- α , interleukin-6 and interleukin-8 from normal human peripheral blood mononuclear cells stimulated by <i>Rhodococcus equi</i> . <i>Veterinary Microbiology</i> , 1997, 56, 277-285.	0.8	5
321	Cerebrospinal Fluid Cytokines in Patients with Tuberculous Meningitis. <i>Clinical Immunology and Immunopathology</i> , 1997, 84, 171-176.	2.1	75
322	Central nervous system involvement as a relapse of disseminated histoplasmosis in an Italian AIDS patient. <i>Journal of Infection</i> , 1997, 35, 83-84.	1.7	15
323	Marked activation of the tumour necrosis factor system in AIDS-associated cryptococcosis. <i>Aids</i> , 1996, 10, 1436-1438.	1.0	7
324	Autoreactive cytotoxic T lymphocytes in human immunodeficiency virus type 1-infected subjects.. <i>Journal of Experimental Medicine</i> , 1996, 183, 2509-2516.	4.2	47

#	ARTICLE	IF	CITATIONS
325	Cerebrospinal fluid antiganglioside antibodies in patients with AIDS. <i>Infection</i> , 1995, 23, 288-291.	2.3	7
326	Defective production of interferon- $\hat{1}^3$ and tumour necrosis factor- $\hat{1}^{\pm}$ by AIDS mononuclear cells after in vitro exposure to <i>Rhodococcus equi</i> . <i>Mediators of Inflammation</i> , 1995, 4, 306-309.	1.4	8
327	<i>Rhodococcus equi</i> Virulence-Associated Antigens and Specific Antibody Response in AIDS Patients Infected with <i>R. equi</i> . <i>Clinical Microbiology and Infection</i> , 1995, 1, 18-23.	2.8	6
328	Tumour Necrosis Factor- $\hat{1}^{\pm}$ Production and Immune Cell Activation in Tuberculous Meningitis. <i>Mediators of Inflammation</i> , 1994, 3, 57-60.	1.4	3
329	Cytomegalovirus encephalitis in two patients with AIDS receiving ganciclovir for cytomegalovirus retinitis. <i>Journal of Infection</i> , 1994, 29, 331-337.	1.7	12
330	Detection of cytomegalovirus-matrix protein (pp65) in leukocytes of HIV-infected patients with painful peripheral neuropathy. <i>Journal of Medical Virology</i> , 1994, 44, 172-175.	2.5	14
331	Humoral Immune Response to <i>Rhodococcus equi</i> in AIDS Patients with <i>R. equi</i> Pneumonia. <i>Journal of Infectious Diseases</i> , 1994, 169, 1179-1180.	1.9	11
332	Myelin degrading activity in the CSF of HIV-1-infected patients with neurological diseases. <i>NeuroReport</i> , 1994, 6, 157-160.	0.6	17
333	Cranial salmonella abscess with parietal bone osteomyelitis in an HIV-infected patient. <i>Aids</i> , 1992, 6, 749.	1.0	11
334	Cerebrospinal fluid myelin basic protein in AIDS dementia complex. <i>Aids</i> , 1992, 6, 1214.	1.0	3
335	Cerebrospinal fluid myelin basic protein as predictive marker of demyelination in AIDS dementia complex. <i>Journal of Neuroimmunology</i> , 1992, 36, 251-254.	1.1	30
336	Cerebrospinal fluid markers for the monitoring of AIDS dementia complex severity. <i>Aids</i> , 1991, 5, 464.	1.0	13
337	Detection of mycobacterial antigen by dot blot assay in the cerebrospinal fluid of patients with tuberculous meningitis. <i>Journal of Infection</i> , 1991, 22, 106-107.	1.7	11
338	Detection of cerebrospinal fluid antibodies against myelin basic protein in patients with AIDS dementia complex. <i>Molecular and Chemical Neuropathology</i> , 1991, 14, 227-236.	1.0	16
339	Serum $\hat{1}^2$ -M in asymptomatic HIV-infected patients treated with zidovudine. <i>Aids</i> , 1990, 4, 1297.	1.0	5
340	Humoral and cellular immune responses to salmonella typhi in patients with typhoid fever. <i>Journal of Clinical Laboratory Analysis</i> , 1989, 3, 191-195.	0.9	6
341	Anticardiolipin antibody in the acquired immunodeficiency syndrome: a marker of <i>Pneumocystis carinii</i> infection?. <i>Journal of Infection</i> , 1989, 18, 100-101.	1.7	4
342	Use of dot immunobinding assay (DIB) for the rapid diagnosis of human brucellosis. <i>Journal of Infection</i> , 1987, 14, 88-89.	1.7	7

#	ARTICLE	IF	CITATIONS
343	Human Amoebiasis: The Interaction of Lymphocyte Surface-Bound Immune Complexes and Pmns Impairs T Cell Proliferative Responses to E. Histolytica Mitogen. Immunological Investigations, 1985, 14, 131-144.	1.0	2